VDAC2 and Bak scarcity in liver mitochondria enables targeting hepatocarcinoma while sparing hepatocytes

Area of Science:

• Molecular Biology
• Cancer Research
• Cell Biology

Background:

• Identifying differences between normal and tumor tissues is crucial for targeted cancer therapies.
• Mitochondrial outer membrane permeabilization is a key step in apoptosis.
• The Bcl-2 family proteins regulate mitochondrial apoptosis.

Purpose of the Study:

• To investigate the role of VDAC2 and Bak in liver cancer cell mitochondria.
• To explore VDAC2 and Bak as potential therapeutic targets for liver cancer.
• To develop strategies for selectively targeting hepatocarcinoma cells.

Main Methods:

• Analysis of VDAC2 and Bak expression in normal liver tissue and human liver cancers.
• Assessment of mitochondrial sensitivity to truncated Bid (tBid) in cancer cell lines.
• In vitro and in vivo testing of combination therapies targeting the tBid pathway and Bcl-2 family proteins.

Main Results:

• Normal hepatocytes exhibit mitochondrial resistance to tBid due to low VDAC2 and Bak levels.
• Hepatocarcinoma cells show increased VDAC2 and Bak, leading to tBid sensitivity.
• Combination therapy of tBid pathway activators and Bcl-2 inhibitors selectively induces death in hepatocarcinoma cells.
• In vivo, Mcl-1 inhibitor (S63845) combined with TRAIL peptide reduced tumor growth in VDAC2-expressing tumors.

Conclusions:

• VDAC2 and Bak levels serve as a mitochondrial molecular fingerprint to distinguish liver cancer from normal tissue.
• Targeting the VDAC2-dependent mitochondrial pathway offers a strategy for selective hepatocarcinoma treatment.
• Combination therapies can effectively eliminate cancer cells while sparing normal hepatocytes.